99586-84-2

Basic information

• Product Name: Methyl 3-chloro-2-methylbenzoate
• Synonyms: Methyl 3-chloro-2-methylbenzoate;3-Chloro-2-methyl-benzoic acid methyl ester
• CAS NO: 99586-84-2
• Molecular Formula: C₉H₉ClO₂
• Molecular Weight: 184.61956
• Product Categories: Acids & Esters;Chlorine Compounds
• Mol File: 99586-84-2.mol
• Article Data: 12

Chemical Properties

• Melting Point: 16.5 °C
• Boiling Point: 243.6°C at 760 mmHg
• Flash Point: 111.2°C
• Appearance: /
• Density: 1.186g/cm³
• Vapor Pressure: 0.0318mmHg at 25°C
• Refractive Index: 1.525
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Methyl 3-chloro-2-methylbenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 3-chloro-2-methylbenzoate(99586-84-2)
• EPA Substance Registry System: Methyl 3-chloro-2-methylbenzoate(99586-84-2)

Safety Data

• Hazardous Substances Data: 99586-84-2(Hazardous Substances Data)

Usage

General Description

Methyl 3-chloro-2-methylbenzoate is a chemical compound with the molecular formula C9H9ClO2. It is a white to light yellow crystalline solid with a molecular weight of 182.62 g/mol. Methyl 3-chloro-2-methylbenzoate is commonly used in the pharmaceutical and chemical industries as an intermediate in the synthesis of various organic compounds. It is also utilized in the manufacturing of fragrances and flavors. Methyl 3-chloro-2-methylbenzoate is known to be a skin and eye irritant and should be handled with care. Additionally, it is important to follow proper safety protocols and guidelines when working with this chemical.

InChI:InChI=1/C9H9ClO2/c1-6-7(9(11)12-2)4-3-5-8(6)10/h3-5H,1-2H3

Upstream product

• 7499-08-3 3-chloro-2-methylbenzoic acid 
• 74-88-4 methyl iodide 
• 67-56-1 methanol 

Downstream Products

• 188187-03-3 2-bromomethyl-3-chloro-benzoic acid methyl ester 
• 871723-37-4 4-chloroisoindolin-1-one 
• 1449754-12-4 C₂₁H₂₈ClF₂N₃O₃ 
• 1427058-75-0 2-(bromomethyl)-1-chloro-3-(difluoromethyl)benzene 
• 1379323-52-0 2-(bromomethyl)-3-chlorobenzaldehyde 
• 1379313-10-6 [2-(bromomethyl)-3-chlorophenyl]methanol 
• 90369-75-8 (3-chloro-2-methyl-phenyl)methanol 
• 1427309-44-1 tert-butyl 4-[(3S,4R)-3-[2-(tert-butoxy)-2-oxoethyl]-1-{[2-chloro-6-(difluoromethyl)phenyl]methyl}-4-methylpyrrolidin-3-amido]piperidine-1-carboxylate 
• 1427058-40-9 2-[(3S,4R)-1-{[2-chloro-6-(difluoromethyl)phenyl]methyl}-3-{[1-(cyclohex-1-en-1-ylmethyl)piperidin-4-yl]carbamoyl}-4-methylpyrrolidin-3-yl]acetic acid 
• 1427309-42-9 tert-butyl 2-[(3S,4R)-1-{[2-chloro-6-(difluoromethyl)phenyl]methyl}-3-[(1-hexylpiperidin-4-yl)carbamoyl]-4-methylpyrrolidin-3-yl]acetate 

Relevant articles and documents

HPK1 ANTAGONISTS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.

PYRROLIDINE-3-YLACETIC ACID DERIVATIVE

A compound represented by formula (1) or a pharmaceutically acceptable salt thereof has an inhibitory effect in the fractalkine-CX3CR1 pathway: wherein R represents a C1-6 alkyl group unsubstituted or having 1 to 3 substituents selected from Substituent Group A, a C3-8 cycloalkyl group unsubstituted or having 1 to 3 substituents selected from Substituent Group A, or a C3-8 cycloalkenyl group unsubstituted or having 1 to 3 substituents selected from Substituent Group A, X represents a C1-6 alkyl group, Y and Z are the same or different from each other and each represents a halogen atom or a C1-6 alkyl group unsubstituted or having 1 to 3 substituents selected from Substituent Group B, n represents 0 or 1, Substituent Group A consists of halogen atoms, and Substituent Group B consists of halogen atoms.

Isosteric analogs of lenalidomide and pomalidomide: Synthesis and biological activity

A series of analogs of the immunomodulary drugs lenalidomide (1) and pomalidomide (2), in which the amino group is replaced with various isosteres, was prepared and assayed for immunomodulatory activity and activity against cancer cell lines. The 4-methyl and 4-chloro analogs 4 and 15, respectively, displayed potent inhibition of tumor necrosis factor-α (TNF-α) in LPS-stimulated hPBMC, potent stimulation of IL-2 in a human T cell co-stimulation assay, and anti-proliferative activity against the Namalwa lymphoma cell line. Both of these analogs displayed oral bioavailability in rat.